S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.76%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.76%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.76%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.76%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)

Amicus Therapeutics (FOLD) ESG Score & Sustainability Data

$10.68
-0.54 (-4.81%)
(As of 04:00 PM ET)

Key ESG Takeaways for Amicus Therapeutics

The key takeaways are AI-generated and highlight the main contributors behind the net impact scores of Amicus Therapeutics. The insights are based on millions of scientific articles, along with the company-specific product and service portfolio.
  • Amicus Therapeutics seems to create the most significant positive value in categories , , and . The largest positive contribution comes from its impact, which is mostly driven by its Fabry disease medication, Clinical research services for genetic diseases, and Preclinical research services for physical health products.
  • Amicus Therapeutics uses resources or causes negative impacts mostly in categories , , and . The negative contribution in the impact category seems to be driven mostly by its Fabry disease medication, Preclinical research services for physical health, and Clinical research services for genetic diseases products.
  • To improve its net impact, a company can either grow its positive impacts, or reduce its negative impacts. For example, by doubling its Preclinical research services for physical health business, Amicus Therapeutics would improve its net impact ratio by 3 percentage points.

FOLD Impact Ratio

Net impact ratio represents the net impact of a company. It is defined as the (positive impacts - negative impacts) / positive impacts. The maximum value for net impact ratio is 100%, representing a theoretical company with no negative impacts. The minimum value is -∞. Net scores depend on the value sets that determine the importance of different impact categories.
+63.5%
The default value set, where each category is given the same weight.

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Millennials
Value set of millennials (b. 1980 - 1999), based on Upright's annual Impact at Work survey.
+69.4%
Most Wanted Workforce
Value set of the most wanted workforce, based on Upright's annual Impact at Work survey.
+57.3%
Society First
Value set that emphasizes society impacts over other impacts.
+30.4%
Knowledge First
Value set that emphasizes knowledge impacts over other impacts.
+83.9%
Health First
Value set that emphasizes health impacts over other impacts.
+78.4%

Amicus Therapeutics ESG Score + Net Impact Profile

ImpactNegativeScorePositive
+1.30
+1.30
+1.84
+1.84
+0.04
+0.04
-0.01
-0.01
+0.00
-0.00
+0.14
+0.15
+0.01
+0.01
+3.03
+3.03
-0.00
+0.00
+0.00
-2.12
-2.12
-0.56
+3.47
+4.03
-0.03
+0.29
+0.32
0.00
+0.00
-0.00
+0.00
+0.00
-0.00
+0.29
+0.29
-0.77
-0.77
+0.01
-0.08
-0.08
+0.00
-0.02
-0.02
+0.00
-0.02
-0.02
+0.00
-0.40
-0.40
+0.00

Upright Model Version 0.8.0
ESG Data Last Updated: March 15, 2023

About Upright's Net Impact Model

Upright's Net Impact Data quantifies the holistic value creation and impact of companies. It details both the negative and positive impacts a company has on the environment, health of people, society and knowledge, and forms a net sum of these costs and gains based on the economic costs of each impact category. The data is produced by Upright's Net Impact model, which is a mathematical model of the economy that produces continuously updated estimates of the net impact of companies by means of an information integration algorithm. The data is primarily sourced from the CORE open access database, which contains over 200 million scientific papers. Other sources of data include open databases published by the World Bank, IMF, WHO, OECD, IPCC, CDC and USDA.

Amicus Therapeutics ESG Score - Frequently Asked Questions

How is Amicus Therapeutics doing in terms of sustainability?

According to The Upright Project, which measures holistic value creation and impact of companies, Amicus Therapeutics has a net impact ratio of 63.5%, indicating an overall positive sustainability impact. Amicus Therapeutics seems to create the most significant positive value in the categories of Physical diseases, Creating knowledge, and Taxes. Amicus Therapeutics uses resources or causes negative impacts mostly in the categories of Scarce human capital, GHG emissions, and Physical diseases. Learn more on the sustainability of Amicus Therapeutics.


More ESG Stocks and Research Tools

This page (NASDAQ:FOLD) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners